Explore

Rapid Read Rapid Read
Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection

Grail, a healthcare company based in Silicon Valley, has developed a $950 blood test called Galleri, designed to detect over 50 types of cancer early. The company presented its largest study at the American Society of Clinical Oncology meeting in Chicago, involving over 140,000 older participants in the UK. The study aimed to determine if the Galleri test could detect cancer before it reached advanced stages. While the test identified additional cancer cases, it missed a significant number, with a sensitivity of around 30%. The test is not yet FDA-approved but is available in the U.S. with a prescription. Despite its limitations, the test showed potential in detecting certain early-stage cancers, such as ovarian and esophageal cancers.
Rapid Read Rapid Read
Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail, a Silicon Valley healthcare company, has presented its largest study to date on the Galleri blood test at the American Society of Clinical Oncology meeting in Chicago. The test, priced at $950, aims to detect over 50 types of cancer by identifying cancer DNA in the bloodstream. The study involved more than 140,000 older individuals in the UK, assessing the test's ability to detect cancer before it reaches advanced stages. While the test increased cancer detection rates when combined with standard screenings, it was less effective at identifying early-stage cancers, which are generally easier to treat. The test is not yet FDA-approved but is available in the U.S. with a prescription.
Rapid Read Rapid Read
GRAIL's NHS-Galleri Trial Shows Significant Reduction in Stage IV Cancer Diagnoses

GRAIL's NHS-Galleri Trial Shows Significant Reduction in Stage IV Cancer Diagnoses

GRAIL, Inc. has announced the results of its NHS-Galleri trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial, conducted in collaboration with NHS England, evaluated the Galleri multi-cancer early detection (MCED) test. Over three years, the trial involved 142,250 participants aged 50 to 77. The results showed a 22% reduction in Stage IV cancer diagnoses in the second screening round and a 26% reduction in the third round. The Galleri test increased cancer detection rates four-fold when added to standard screening, and reduced emergency cancer diagnoses by 25%. The trial aims to detect cancers earlier, potentially allowing for curative treatment.
Trendline Trendline
Illumina Launches New MRD Kit to Enhance Cancer Research Capabilities

Illumina Launches New MRD Kit to Enhance Cancer Research Capabilities

Illumina Launches New MRD Kit to Enhance Cancer Research Capabilities
Trendline Trendline
AI Enhances Gene-Based Cancer Detection at ASCO26, Says Caris Life Sciences President

AI Enhances Gene-Based Cancer Detection at ASCO26, Says Caris Life Sciences President

AI Enhances Gene-Based Cancer Detection at ASCO26, Says Caris Life Sciences President
Trendline Trendline
Deloitte Report Highlights Shift to Consumer-Driven Diagnostics in Healthcare

Deloitte Report Highlights Shift to Consumer-Driven Diagnostics in Healthcare

Deloitte Report Highlights Shift to Consumer-Driven Diagnostics in Healthcare
Trendline Trendline
Deloitte Report Highlights AI and Interoperability Challenges in Consumer-Driven Diagnostics

Deloitte Report Highlights AI and Interoperability Challenges in Consumer-Driven Diagnostics

Deloitte Report Highlights AI and Interoperability Challenges in Consumer-Driven Diagnostics
Rapid Read Rapid Read
FDA Grants Breakthrough Device Designation to Gene Solutions' SPOT-MAS 10 for Cancer Screening

FDA Grants Breakthrough Device Designation to Gene Solutions' SPOT-MAS 10 for Cancer Screening

Gene Solutions, a biotechnology company, has received the U.S. FDA Breakthrough Device Designation for its SPOT-MAS 10 multi-omic blood test. This test is designed to detect cancer-associated signals by analyzing circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm. The test is intended for use as an adjunctive screening tool in asymptomatic adults aged 40 and older, covering various cancers such as breast, lung, and colorectal. The designation highlights the test's potential to provide more effective diagnosis of life-threatening diseases compared to current options. SPOT-MAS 10 aims to complement existing screening programs and expand opportunities for cancers lacking established pathways.
Rapid Read Rapid Read
Blood Testing Added to Colorectal Cancer Screening Recommendations by American Cancer Society

Blood Testing Added to Colorectal Cancer Screening Recommendations by American Cancer Society

The American Cancer Society has updated its colorectal cancer screening guidelines to include blood testing as an option for adults aged 45 and older. This addition aims to provide an alternative for individuals who decline or cannot complete traditional screening methods like colonoscopies or stool-based tests. The blood test, known as the Shield test, was approved by the FDA in 2024 and offers a less invasive option for detecting colorectal cancer.
Trendline Trendline
Reid Hoffman Highlights AI's Potential in Drug Discovery as Next Major Market Opportunity

Reid Hoffman Highlights AI's Potential in Drug Discovery as Next Major Market Opportunity

Reid Hoffman Highlights AI's Potential in Drug Discovery as Next Major Market Opportunity
Trendline Trendline
Cardio Diagnostics Holdings to Present Precision Cardiovascular Solutions at National Conferences

Cardio Diagnostics Holdings to Present Precision Cardiovascular Solutions at National Conferences

Cardio Diagnostics Holdings to Present Precision Cardiovascular Solutions at National Conferences
Rapid Read Rapid Read
Experimental Pill AD109 Shows Promise in Reducing Sleep Apnea Symptoms

Experimental Pill AD109 Shows Promise in Reducing Sleep Apnea Symptoms

AD109, an experimental pill developed by Apnimed, has shown promising results in reducing symptoms of sleep apnea by 44% in a Phase 3 clinical trial. The drug, a combination of aroxybutynin and atomoxetine, aims to replace CPAP machines by improving airway function during sleep. The trial involved participants with obstructive sleep apnea who could not use CPAP, and results indicated significant improvements in their apnea-hypopnea index. Despite the promising data, some sleep doctors remain skeptical about the drug's effectiveness, particularly for severe cases of sleep apnea.